STOCK TITAN
  1. Home
  2. News
  3. ARQT

Arcutis Biotherapeutics Inc - ARQT STOCK NEWS

IMPACT
SENTIMENT
ARQT : Nasdaq
Arcutis Presents Positive Patient-Reported Outcome Data from the Pivotal ARRECTOR Phase 3 Trial in Scalp and Body Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
clinical trial
IMPACT
SENTIMENT
ARQT : Nasdaq
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11
fda approval
IMPACT
SENTIMENT
ARQT : Nasdaq
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMPACT
SENTIMENT
ARQT : Nasdaq
Arcutis Appoints L. Todd Edwards as Chief Commercial Officer
management
IMPACT
SENTIMENT
ARQT : Nasdaq
New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis
IMPACT
SENTIMENT
ARQT : Nasdaq
Arcutis Announces Positive Results from INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5
clinical trial
IMPACT
SENTIMENT
ARQT : Nasdaq
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IMPACT
SENTIMENT
ARQT : Nasdaq
Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older
IMPACT
SENTIMENT
ARQT : Nasdaq
Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD)
IMPACT
SENTIMENT
ARQT : Nasdaq
Arcutis to Present at Upcoming Investor Conference
conferences
Stock ARQT logo
Arcutis Biotherapeutics Inc
Nasdaq:ARQT

ARQT Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About ARQT

arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.